Publication
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- drugAntiestrogen Therapycivic_curation1.00
- drugCDK4/6 Inhibitioncivic_curation1.00
- geneFGFR1civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
- variantFGFR1 Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 30914635
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR1 Amplification + ZNF703 AmplificationFGFR1ZNF7031 | ||||||||
| Letrozole + RibociclibCombination | Malignant Breast Neoplasm | Predictive | B | Supports Resistance | 3 | submitted | EID12531In a cohort of 427 patients from the MONALEESA-2 study, which compared aramotase inhibitor letrozole plus CDK4/6 inhibitor ribociclib vs. letrozole plus placebo in patients with ER+/HER2− advanced bre… (full text at CIViC) PMID 30914635 · Formisano et al., 2019 · Open in CIViC | civic |
| FGFR1 Amplification + FGFR1 Overexpression1 | ||||||||
| Antiestrogen Therapy + CDK4/6 InhibitionCombination | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | D | Supports Resistance | 4 | accepted | EID12557In a cell line screen using MCF-7, exogenous expression of FGFR1 confers resistance to fulvestrant and fulvestrant plus ribociclib. In a study using breast cancer cell lines MCF-7 and T47D, overexpres… (full text at CIViC) PMID 30914635 · Formisano et al., 2019 · Open in CIViC | civic |